Literature DB >> 33824165

A PERFECT Biomarker-focused Study of Neoadjuvant IO for Esophagogastric Cancer.

Daniel V T Catenacci1.   

Abstract

To evaluate feasibility and efficacy, checkpoint inhibitor atezolizumab was added to neoadjuvant chemoradiotherapy prior to surgery for esophagogastric adenocarcinoma. The approach was deemed feasible, and while it did not demonstrate better clinical outcome to propensity-matched patients, biomarker investigation demonstrated that high inflammation in the sample at baseline predicted therapeutic benefit.See related article by van den Ende et al., p. 3351. ©2021 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33824165      PMCID： PMC8197732          DOI： 10.1158/1078-0432.CCR-21-0324

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  4 in total

1.  The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation.

Authors:  Ronan J Kelly; Ali H Zaidi; Matthew A Smith; Ashten N Omstead; Juliann E Kosovec; Daisuke Matsui; Samantha A Martin; Christina DiCarlo; E Day Werts; Jan F Silverman; David H Wang; Blair A Jobe
Journal:  Ann Surg       Date:  2018-12       Impact factor: 12.969

2.  Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline.

Authors:  Manish A Shah; Erin B Kennedy; Daniel V Catenacci; Dana C Deighton; Karyn A Goodman; Narinder K Malhotra; Christopher Willett; Brendon Stiles; Prateek Sharma; Laura Tang; Bas P L Wijnhoven; Wayne L Hofstetter
Journal:  J Clin Oncol       Date:  2020-06-22       Impact factor: 44.544

3.  Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types.

Authors:  Tom van den Ende; Héctor G van den Boorn; Nadine M Hoonhout; Faridi S van Etten-Jamaludin; Sybren L Meijer; Sarah Derks; Tanja D de Gruijl; Maarten F Bijlsma; Martijn G H van Oijen; Hanneke W M van Laarhoven
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-06-12       Impact factor: 10.680

4.  Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT).

Authors:  Tom van den Ende; Nicolien C de Clercq; Mark I van Berge Henegouwen; Suzanne S Gisbertz; E D Geijsen; R H A Verhoeven; Sybren L Meijer; Sandor Schokker; M P G Dings; Jacques J G H M Bergman; Nadia Haj Mohammad; Jelle P Ruurda; Richard van Hillegersberg; Stella Mook; Max Nieuwdorp; Tanja D de Gruijl; Tanya T D Soeratram; Bauke Ylstra; Nicole C T van Grieken; Maarten F Bijlsma; Maarten C C M Hulshof; H W M van Laarhoven
Journal:  Clin Cancer Res       Date:  2021-01-27       Impact factor: 12.531
  4 in total
  1 in total

Review 1.  Immune-Checkpoint Inhibition in the Treatment of Gastro-Esophageal Cancer: A Closer Look at the Emerging Evidence.

Authors:  Koosha Paydary; Natalie Reizine; Daniel V T Catenacci
Journal:  Cancers (Basel)       Date:  2021-11-25       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.